Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: An acute and 12-week randomised, double-blind, placebo-controlled trial

European Journal of Endocrinology

Volumn 176, Issue 1, 2017, Pages 77-86

  Smits, Mark M ^a   Tonneijck, Lennart ^a   Muskiet, Marcel H A ^a   Hoekstra, Trynke ^a,b   Kramer, Mark H H ^a   Diamant, Michaela ^a   Van Raalte, Daniël H ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; HEMOGLOBIN A1C; LIRAGLUTIDE; METFORMIN; SITAGLIPTIN; SULFONYLUREA; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE BLOOD LEVEL; PEPTIDE; SULFONYLUREA DERIVATIVE; VENOM;

ADRENERGIC SYSTEM; ADULT; ARTERIAL STIFFNESS; ARTICLE; AUGMENTATION INDEX; BLOOD PRESSURE; BODY MASS; BODY SURFACE; CONTROLLED STUDY; DIABETIC PATIENT; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; EVENING DOSAGE; EXERCISE; FEMALE; HEADACHE; HEART INDEX; HEART OUTPUT; HEART RATE VARIABILITY; HEART STROKE VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MEDICATION COMPLIANCE; MIDDLE AGED; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHOTOELECTRIC PLETHYSMOGRAPHY; POLLAKISURIA; PRIORITY JOURNAL; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; RESTING HEART RATE; SYSTOLIC BLOOD PRESSURE; TONOMETRY; TREATMENT DURATION; VASCULAR RESISTANCE; VOMITING; AGED; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; HEART RATE; METABOLISM; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

AGED; BLOOD GLUCOSE; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HEART RATE; HUMANS; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; MALE; METFORMIN; MIDDLE AGED; PEPTIDES; SULFONYLUREA COMPOUNDS; TREATMENT OUTCOME; VENOMS;

EID: 85002397965     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-16-0507     Document Type: Article

References (34)

1. Ussher JR & Drucker DJ. Cardiovascular actions of incretin-based therapies. Circulation Research 2014 114 1788-1803. (doi:10.1161/CIRCRESAHA.114.301958)
2. Barragán JM, Rodríguez RE, Eng J & Blázquez E. Interactions of exendin-(9-39) with the effects of glucagon-like peptide-1-(7-36) amide and of exendin-4 on arterial blood pressure and heart rate in rats. Regulatory Peptides 1996 67 63-68. (doi:10.1016/s0167-0115(96)00113-9)
3. Smits MM, Muskiet MHA, Tonneijck L, Hoekstra T, Kramer MHH, Diamant M & van Raalte DH. Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males. British Journal of Clinical Pharmacology 2016 81 613-620. (doi:10.1111/bcp.12843)
4. Sun F, Wu S, Guo S, Yu K, Yang Z, Li L, Zhang Y, Quan X, Ji L & Zhan S. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Research and Clinical Practice 2015 110 26-37. (doi:10.1016/j.diabres.2015.07.015)
5. Nakatani Y, Kawabe A, Matsumura M, Aso Y, Yasu T, Banba N & Nakamoto T. Effects of GLP-1 receptor agonists on heart rate and the autonomic nervous system using holter electrocardiography and power spectrum analysis of heart rate variability. Diabetes Care 2016 39 e22-e23. (doi: 10.2337/dc15-1437)
6. Meier JJ, Rosenstock J, Hincelin-Méry A, Roy-Duval C, Delfolie A, Coester H-V, Menge BA, Forst T & Kapitza C. Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized, open-label trial. Diabetes Care 2015 38 1263-1273. (doi:10.2337/dc14-1984)
7. Jensen MT, Suadicani P, Hein HO & Gyntelberg F. Elevated resting heart rate, physical fitness and all-cause mortality: a 16-year follow-up in the Copenhagen Male Study. Heart 2013 99 882-887. (doi:10.1136/heartjnl-2012-303375)
8. Arnold JM, Fitchett DH, Howlett JG, Lonn EM & Tardif J-C. Resting heart rate: a modifiable prognostic indicator of cardiovascular risk and outcomes? Canadian Journal of Cardiology 2008 24 (Supplement A) 3A-8A. (doi:10.1016/S0828-282X(08)71019-5)
9. Diaz A, Bourassa MG, Guertin M-C & Tardif J-C. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. European Heart Journal 2005 26 967-974. (doi:10.1093/eurheartj/ehi190)
10. Mendis B, Simpson E, MacDonald I & Mansell P. Investigation of the haemodynamic effects of exenatide in healthy male subjects. British Journal of Clinical Pharmacology 2012 74 437-444. (doi:10.1111/j.1365-2125.2012.04214.x)
11. Bharucha AE, Charkoudian N, Andrews CN, Camilleri M, Sletten D, Zinsmeister AR & Low PA. Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans. American Journal of Physiology Regulatory Integrative and Comparative Physiology 2008 295 R874-R880. (doi:10.1152/ajpregu.00153.2008)
12. Smits MM, van Raalte DH, Tonneijck L, Muskiet MHA, Kramer MHH & Cahen DL. GLP-1 based therapies: clinical implications for gastroenterologists. Gut 2016 65 702-711. (doi:10.1136/gutjnl-2015-310572)
13. Smits MM, Tonneijck L, Muskiet MHA, Hoekstra T, Kramer MHH, Pieters IC, Cahen DL, Diamant M & van Raalte DH. Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes. BMJ Open 2015 5 e009579. (doi:10.1136/bmjopen-2015-009579)
14. Ewing DJ & Clarke BF. Diagnosis and management of diabetic autonomic neuropathy. British Medical Journal (Clinical Research Edition) 1982 285 916-918. (doi:10.1136/bmj.285.6346.916)
15. Fehse F, Trautmann M, Holst JJ, Halseth AE, Nanayakkara N, Nielsen LL, Fineman MS, Kim DD & Nauck MA. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 2005 90 5991-5997. (doi:10.1210/jc.2005-1093)
16. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation 1996 93 1043-1065. (doi:10.1161/01.cir.93.5.1043)
17. Nauck MA, Baranov O, Ritzel RA & Meier JJ. Do current incretin mimetics exploit the full therapeutic potential inherent in GLP-1 receptor stimulation? Diabetologia 2013 56 1878-1883. (doi:10.1007/s00125-013-2953-6)
18. Stratton JR, Pfeifer MA & Halter JB. The hemodynamic effects of sympathetic stimulation combined with parasympathetic blockade in man. Circulation 1987 75 922-929. (doi:10.1161/01.CIR.75.5.922)
19. Ferdinand KC, White WB, Calhoun DA, Lonn EM, Sager PT, Brunelle R, Jiang HH, Threlkeld RJ, Robertson KE & Geiger MJ. Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. Hypertension 2014 64 731-737. (doi:10.1161/HYPERTENSIONAHA.114.03062)
20. Bonyhay I, Jokkel G & Kollai M. Relation between baroreflex sensitivity and carotid artery elasticity in healthy humans. American Journal of Physiology 1996 271 H1139-H1144.
21. Pyke C, Heller RS, Kirk RK, Orskov C, Reedtz-Runge S, Kaastrup P, Hvelplund A, Bardram L, Calatayud D & Knudsen LB. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 2014 155 1280-1290. (doi:10.1210/en.2013-1934)
22. Larsson HP. How is the heart rate regulated in the sinoatrial node? Another piece to the puzzle. Journal of General Physiology 2010 136 237-241. (doi:10.1085/jgp.201010506)
23. Zima E, Lippert M, Czygan G & Merkely B. Determination of left ventricular volume changes by intracardiac conductance using a biventricular electrode configuration. Europace 2006 8 537-544. (doi:10.1093/europace/eul057)
24. Edwards CM, Todd JF, Ghatei MA & Bloom SR. Subcutaneous glucagon-like peptide-1 (7-36) amide is insulinotropic and can cause hypoglycaemia in fasted healthy subjects. Clinical Science 1998 95 719-724. (doi:10.1042/cs0950719)
25. Asmar A, Simonsen L, Asmar M, Madsbad S, Holst JJ, Frandsen E, Moro C, Jonassen T & Bülow J. Renal extraction and acute effects of glucagon-like peptide-1 on central and renal hemodynamics in healthy men. American Journal of Physiology: Endocrinology and Metabolism 2015 308 E641-E649. (doi:10.1152/ajpendo.00429.2014)
26. Buckberg GD, Fixler DE, Archie JP & Hoffman JI. Experimental subendocardial ischemia in dogs with normal coronary arteries. Circulation Research 1972 30 67-81. (doi:10.1161/01.RES.30.1.67)
27. Sun F, Yu K, Wu S, Zhang Y, Yang Z, Shi L, Ji L & Zhan S. Cardiovascular safety and glycemic control of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus: a pairwise and network meta-analysis. Diabetes Research and Clinical Practice 2012 98 386-395. (doi:10.1016/j.diabres.2012.09.004)
28. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, Lawson FC, Ping L, Wei X, Lewis EF et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. New England Journal of Medicine 2015 373 2247-2257. (doi:10.1056/NEJMoa1509225)
29. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine 2016 375 311-322. (doi:10.1056/NEJMoa1603827)
30. Bogert LWJ, Wesseling KH, Schraa O, Van Lieshout EJ, de Mol BAJM, van Goudoever J, Westerhof BE & van Lieshout JJ. Pulse contour cardiac output derived from non-invasive arterial pressure in cardiovascular disease. Anaesthesia 2010 65 1119-1125. (doi:10.1111/j.1365-2044.2010.06511.x)
31. Rowe JW, Young JB, Minaker KL, Stevens AL, Pallotta J & Landsberg L. Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man. Diabetes 1981 30 219-225. (doi:10.2337/diab.30.3.219)
32. Fagius J, Niklasson F & Berne C. Sympathetic outflow in human muscle nerves increases during hypoglycemia. Diabetes 1986 35 1124-1129. (doi:10.2337/diab.35.10.1124)
33. Berkelaar M, Eekhoff EMW, Simonis-Bik AMC, Boomsma DI, Diamant M, Ijzerman RG, Dekker JM, 't Hart LM & de Geus EJC. Effects of induced hyperinsulinaemia with and without hyperglycaemia on measures of cardiac vagal control. Diabetologia 2013 56 1436-1443. (doi:10.1007/s00125-013-2848-6)
34. Trahair LG, Horowitz M, Hausken T, Feinle-Bisset C, Rayner CK & Jones KL. Effects of exogenous glucagon-like peptide-1 on the blood pressure, heart rate, mesenteric blood flow and glycemic responses to intraduodenal glucose in healthy older subjects. Journal of Clinical Endocrinology and Metabolism 2014 99 E2628-E2634. (doi:10.1210/jc.2014-2475)